SPY322.64-7.66 -2.32%
DIA267.58-5.23 -1.92%
IXIC10,632.99-330.65 -3.02%

Catabasis Pharmaceuticals And Duchenne UK Announce Partnership To Evaluate Edasalonexent In Phase 2 Non-Ambulatory Duchenne Muscular Dystrophy Trial

Benzinga · 01/08/2020 13:11